FDA declares Novo Nordisk plant, key to drug manufacturing for some biotechs, out of compliance - STAT
FDA declares Novo Nordisk plant, key to drug manufacturing for some biotechs, out of compliance.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on August 24, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated High urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing (503B) facilities that rely on Novo Nordisk's plant for drug manufacturing. should confirm how it applies to their specific situation before acting. There is a time constraint attached: Not specified in the provided text.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The FDA has declared the Novo Nordisk plant out of compliance, which may affect the supply of drugs manufactured there.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, and compounding outsourcing (503B) facilities that rely on Novo Nordisk's plant for drug manufacturing.
What you must do
Assess your supply chain for dependencies on this plant and identify alternative sources or adjust inventory plans.
Deadline
Not specified in the provided text.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Guidance: Compounding Animal Drugs from Bulk Drug Substances: Compounding under CGMP in Federally-Registered Facilities
- FDA to require diversity plan for clinical trials - nature.com
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Second Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661
- FDA Issues Final Rule Clarifying Evidence of Off-Lab... - Dechert
- Schedules of Controlled Substances: Temporary Placement of 5,6-Dichloro Brorphine, 5,6-Dichloro Desmethylchlorphine, N-Propionitrile Chlorphine, and Spirochlorphine in Schedule I of the Controlled Substances Act